Owlet
Owlet's revenue rose 35.4% to $106 million in fiscal 2025. Its operating margin was −7.8%, up from −25.9% a year earlier. Free cash flow was −$11 million. The diluted share count rose 65.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Owlet lost money in fiscal 2025: a net loss of $40 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 95 | 11 | 17 | 20 | 36 |
| Debt incl. finance leases | 16 | 10 | 6 | 12 | 13 |
| Net debt (negative means net cash) | −79 | −1 | −11 | −8 | −22 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.3x | — | — | — | 0.7x |
| Interest coverage | −31.5x | −76.7x | −9.0x | −12.4x | −10.2x |
| Current ratio | 2.0x | 0.8x | 0.9x | 1.3x | 1.9x |
| Quick ratio | 1.7x | 0.5x | 0.7x | 1.0x | 1.5x |
Cash flow
Projections
Project Owlet's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Owlet shares on the open market, and 2 insiders sold $295,978.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Feb 27, 2026 | Amanda CrawfordChief Financial Officer | Sold | 6,892 | $11.50 | $79,258 | Form 4 |
| Feb 26, 2026 | Jonathan HarrisFormer President & CEO | Sold | 12,676 | $11.50 | $145,774 | Form 4 |
| Feb 17, 2026 | Jonathan HarrisFormer President & CEO | Sold | 3,540 | $10.65 | $37,701 | Form 4 |
| Jan 20, 2026 | Jonathan HarrisPresident and CEO | Sold | 2,311 | $13.33 | $30,806 | Form 4 |
| Jan 20, 2026 | Amanda CrawfordChief Financial Officer | Sold | 183 | $13.33 | $2,439 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 5 of 9 | 5 of 9 | 5 of 9 |
| Rule of 40 | −65.5% | 30.1% | 25.0% |
| Altman Z'' | −24.55 | −19.59 | −9.08 |
| Accruals ratio | −18.3% | −2.8% | −42.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Pass |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 5 of 9 | 5 of 9 | 5 of 9 |
Compare
Put Owlet side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Owlet | FY25 | 35.4% | −7.8% | −10.5% | — | — | 5 | |
| Sanara MedTech | FY25 | 19.0% | 7.1% | 2.1% | 13.0% | 2.6x | 3 | Compare |
| Beta Bionics | FY25 | 53.9% | −71.5% | −56.1% | — | — | — | Compare |
| NeuroPace | FY25 | 25.1% | −16.3% | −11.3% | −81.8% | — | 5 | Compare |
| Anika Therapeutics | FY25 | −5.9% | −9.8% | 3.9% | — | — | — | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 75 | 76 | 69 | 54 | 78 | 106 |
| Revenue growth | — | 0.6% | −8.8% | −21.9% | 44.5% | 35.4% |
| Gross profit | 36 | 35 | 23 | 23 | 39 | 54 |
| Research and development | 10 | 21 | 28 | 10 | 10 | 14 |
| Operating income | −7 | −56 | −85 | −29 | −20 | −8 |
| Net income | −10 | −72 | −79 | −33 | −12 | −40 |
| Diluted EPS (US$) | −0.48 | −1.13 | −9.98 | −4.53 | −1.57 | — |
| Diluted shares (millions) | 22 | 63 | 8 | 8 | 11 | 18 |
| Cash flow | ||||||
| Cash from operations | −0 | −41 | −81 | −24 | −11 | −11 |
| Capital expenditure | 1 | 1 | 1 | 0 | 0 | 0 |
| Free cash flow | −1 | −42 | −82 | −24 | −11 | −11 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 4 | 13 | 10 | 9 | 9 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 17 | 95 | 11 | 17 | 20 | 36 |
| Debt incl. finance leases | 12 | 16 | 10 | 6 | 12 | 13 |
| Total assets | 40 | 140 | 58 | 44 | 50 | 86 |
| Total liabilities | 61 | 85 | 69 | 74 | 66 | 50 |
| Shareholders' equity | −68 | 55 | −11 | −38 | −30 | 19 |
| Margins and ratios | ||||||
| Gross margin | 47.6% | 46.2% | 33.7% | 41.8% | 50.4% | 50.6% |
| Operating margin | −9.3% | −73.6% | −122.3% | −53.0% | −25.9% | −7.8% |
| Net margin | −13.9% | −94.5% | −114.6% | −60.9% | −16.1% | −37.5% |
| Free cash flow margin | −1.4% | −54.8% | −118.5% | −43.6% | −14.4% | −10.5% |
| Rule of 40 (growth + FCF margin) | — | −54.2% | −127.3% | −65.5% | 30.1% | 25.0% |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | — | −356.1% | — | — | — |
| Return on assets | — | −79.6% | −80.1% | −64.4% | −26.8% | −58.7% |
| Net debt to EBITDA | — | — | — | — | — | — |